<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02800070</url>
  </required_header>
  <id_info>
    <org_study_id>OZM-074</org_study_id>
    <nct_id>NCT02800070</nct_id>
  </id_info>
  <brief_title>Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease</brief_title>
  <official_title>Clinical Pilot Study of Autologous Stem Cell Transplantation of Cluster of Differentiation 34 Positive (CD34+) Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ozmosis Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human study for the treatment of Fabry disease. Eligible patients will&#xD;
      have an autologous stem cell transplantation using CD34+ cells that are transduced with the&#xD;
      lentivirus vector containing the human alpha-gal A gene. The researchers of this study would&#xD;
      like to see if the re-introduction of transduced cells will help increase the levels of&#xD;
      alpha-gal A enzyme levels and to determine the safety and toxicity of autologous stem cell&#xD;
      transplantation using CD34+ cells transduced with lentivirus vector containing the alpha-gal&#xD;
      A gene. This study's objective is to determine the safety and toxicity of lentivirus&#xD;
      alpha-gal A transduced CD34+ cells in adult males with Fabry disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment</measure>
    <time_frame>5 years</time_frame>
    <description>Safety measurement will be based on all clinical and laboratory assessment post-baseline. The assessment will be the frequency of clinically notable abnormal vital signs and laboratory values, and the frequency of treatment-related adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alpha-gal A enzyme activity levels</measure>
    <time_frame>5 years</time_frame>
    <description>Increase in α-gal A enzyme activity within the plasma, leukocytes, and Bone marrow aspirate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gb3 levels</measure>
    <time_frame>5 years</time_frame>
    <description>Reduction of Gb3 in plasma and urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lyso-Gb3 levels</measure>
    <time_frame>5 years</time_frame>
    <description>Reduction of lyso-Gb3 in plasma and urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lyso-Gb3 analogue (-28)</measure>
    <time_frame>5 years</time_frame>
    <description>Reduction of lyso-Gb3 (-28) in plasma and urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lyso-Gb3 analogue (-2)</measure>
    <time_frame>5 years</time_frame>
    <description>Reduction of lyso-Gb3 (-2) in plasma and urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lyso-Gb3 analogue (+16)</measure>
    <time_frame>5 years</time_frame>
    <description>Reduction of lyso-Gb3 (+16) in plasma and urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lyso-Gb3 analogue (+34)</measure>
    <time_frame>5 years</time_frame>
    <description>Reduction of lyso-Gb3 (+34) in plasma and urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lyso-Gb3 analogue (+50)</measure>
    <time_frame>5 years</time_frame>
    <description>Reduction of lyso-Gb3 (+50) in plasma and urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vector copy number per genome on the CD34+ cell population</measure>
    <time_frame>5 years</time_frame>
    <description>Persistence of LV-transduced cells as measured by quantitative (q)PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transduction efficiency</measure>
    <time_frame>5 years</time_frame>
    <description>Vector copy number per genome on the CD34+ cell population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transduction efficiency</measure>
    <time_frame>5 years</time_frame>
    <description>Number of colonies positive by PCR for the provirus out of number plated in the colony assay</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Health Canada approved transduced autologous CD34+ cell product.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lentivirus Alpha-gal A transduced stem cells</intervention_name>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male patients 18-50 years of age at the time of enrollment&#xD;
&#xD;
          2. Diagnosis of Fabry disease (FD) as defined by very low or absent α-gal A activity&#xD;
&#xD;
          3. Classic FD Type I phenotype with alpha-galactosidase A (GLA) genotyping&#xD;
&#xD;
          4. Patients on enzyme replacement therapy (ERT) prior to enrollment&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1&#xD;
&#xD;
          6. Adequate organ function within 21 days prior to Pre-Treatment Phase:&#xD;
&#xD;
          7. Willing and capable of signing and giving written informed consent in accordance with&#xD;
             Research Ethics Board (REB) requirements&#xD;
&#xD;
          8. Willing to comply with all procedures outlined in the study protocol, cooperative with&#xD;
             the protocol schedule, able to return for safety evaluation, or otherwise likely to&#xD;
             complete the study&#xD;
&#xD;
          9. Willing to abstain from sexual activity or willing to use condoms during sexual&#xD;
             intercourse from day of Melphalan administration on day -1 of Phase 3 until after 12&#xD;
             months follow-up post-transplant.&#xD;
&#xD;
         10. Willing to not donate sperm after receiving Melphalan. Sperm banking will be&#xD;
             recommended to any patient who would like to father children in the future.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Males with variant Fabry Disease.&#xD;
&#xD;
          2. Female gender&#xD;
&#xD;
          3. Use of immunosuppressive agents or any anticoagulant&#xD;
&#xD;
          4. Ongoing ERT-related infusion associated reactions of moderate-to-severe intensity&#xD;
&#xD;
          5. Presence of anti-agalsidase immunoglobulin (Ig)G antibodies above a threshold (5-fold&#xD;
             above normal;) or evidence of high titre neutralizing antibodies&#xD;
&#xD;
          6. Blood test positive for Hepatitis B virus (HBV), Hepatitis C virus (HCV), human&#xD;
             immunodeficiency virus (HIV), human T-cell lymphotropic virus type 1 (HTLV-1), human&#xD;
             T-cell lymphotropic virus type 1 (HTLV-2), or Venereal Disease Research Laboratory&#xD;
             test (VDRL; Transmissible Disease (TD) testing will be done in Pre-Treatment Phase 2 -&#xD;
             see section 5.1 for full panel of TD tests. Patients will only be excluded from the&#xD;
             study if positive for the TD tests listed here in this exclusion).&#xD;
&#xD;
          7. Uncontrolled bacterial, viral, or fungal infections&#xD;
&#xD;
          8. Prior malignancies except resected basal cell carcinoma&#xD;
&#xD;
          9. Chronic Kidney Disease (CKD) stage &gt;2&#xD;
&#xD;
         10. History of heart failure or left ventricle ejection fraction (LVEF) &lt;45% or moderate&#xD;
             to severe diastolic dysfunction by standard criteria&#xD;
&#xD;
         11. Arrhythmia: bundle branch block, heart block degree II or III, atrial fibrillation,&#xD;
             supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation,&#xD;
             cardiac arrest, pacemaker, implantable cardiac defibrillator&#xD;
&#xD;
         12. Coronary artery disease with angina, prior myocardial infarction, percutaneous&#xD;
             transluminal coronary angioplasty with or without stent, coronary artery bypass graft&#xD;
             surgery, moderate to severe valvular heart disease, valve replacement surgery&#xD;
&#xD;
         13. Uncontrolled hypertension&#xD;
&#xD;
         14. Diabetes mellitus&#xD;
&#xD;
         15. Advanced liver disease, liver failure, cirrhosis&#xD;
&#xD;
         16. Immune deficiency state&#xD;
&#xD;
         17. Moderate-to-severe chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
         18. Any hematological condition with white blood cells (WBC) &lt;3.0 x109/L, platelet count&#xD;
             &lt;100 x109/L, and/or hemoglobin &lt;100 g/L&#xD;
&#xD;
         19. Prior bone marrow transplant (BMT) or organ transplant&#xD;
&#xD;
         20. Any condition that would preclude use of Melphalan&#xD;
&#xD;
         21. Use of a drug with cytotoxic or immunosuppressive effect within 60 days of trial entry&#xD;
&#xD;
         22. Uncontrolled psychiatric disorder&#xD;
&#xD;
         23. Active chronic infection&#xD;
&#xD;
         24. Prior tuberculosis&#xD;
&#xD;
         25. Any other serious concurrent disease&#xD;
&#xD;
         26. Cognitive impairment that would prevent informed consent&#xD;
&#xD;
         27. Use of an investigational drug within 30 days of stem cell transplant (SCT)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alberta Children's Hospital, University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QE II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autologous stem cell transplant</keyword>
  <keyword>gene therapy</keyword>
  <keyword>Fabry disease</keyword>
  <keyword>lentivirus</keyword>
  <keyword>haematopoietic stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

